SCHEMBL20875249

SCHEMBL20875249

CC(O)c1nc2cc(B3OC(C)(C)C(C)(C)O3)ccc2n1C

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 1/20 0.37
LPL P06858 4/20 0.35
LIPG Q9Y5X9 4/20 0.35
LMNA P02545 2/20 0.35
KDM4E B2RXH2 1/20 0.35
TDP1 Q9NUW8 1/20 0.34
SMN1; SMN2 Q16637 4/20 0.33
IDO1 P14902 1/20 0.33
TDO2 P48775 1/20 0.33
CYP2D6 P10635 1/20 0.33
KMT2A Q03164 1/20 0.33
MAPK1 P28482 1/20 0.33
HDAC6 Q9UBN7 2/20 0.33
HDAC1 Q13547 1/20 0.33
SNCA P37840 1/20 0.33
ESR2 Q92731 1/20 0.33
TSHR P16473 1/20 0.32
GAA P10253 1/20 0.32
HTT P42858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17419208 1.00 IRAK4 (0.37) IRAK4LPLLIPGLMNAKDM4E
SCHEMBL17420900 0.86 IDO1 (0.38) IRAK4LPLLIPGIDO1TDO2
SCHEMBL6584423 0.80 MAPT (0.44) IRAK4LPLLIPGLMNAKDM4E
SCHEMBL17419195 0.76 IRAK4 (0.39) IRAK4LPLLIPGKDM4EIDO1
SCHEMBL593916 0.74 LPL (0.50) IRAK4LPLLIPGLMNAKDM4E
SCHEMBL29241869 0.73 IRAK4 (0.39) IRAK4LPLLIPGSMN1; SMN2IDO1
SCHEMBL29037572 0.73 MAPT (0.45) IRAK4LPLLIPGKDM4EIDO1
SCHEMBL13313016 0.73 KMT2A (0.50) LMNAKDM4ETDP1SMN1; SMN2CYP2D6
SCHEMBL5141046 0.72 LIPG (0.40) IRAK4LPLLIPGLMNAKDM4E
SCHEMBL23638462 0.70 IRAK4 (0.43) IRAK4LPLLIPGIDO1TDO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190106426-A1 IMIDAZOPYRAZINES AS LSD1 INHIBITORS INCYTE CORPORATION 2019-04-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190106426-A1 IMIDAZOPYRAZINES AS LSD1 INHIBITORS KDM1B, KDM2A, KDM1A IRAK4 1197/4885LPL 4054/4885LIPG 3687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.